Open AccessLenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction
Author(s) -
Satoshi Koyama,
Naritomo Miyake,
Kazunori Fujiwara,
Tsuyoshi Morisaki,
Takahiro Fukuhara,
Hiroya Kitano,
Hiromi Takeuchi
Publication year - 2018
Publication title -
european thyroid journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.23
H-Index - 10
eISSN - 2235-0802
pISSN - 2235-0640
DOI - 10.1159/000485972
Subject(s) - lenvatinib , medicine , anaplastic thyroid cancer , adverse effect , thyroid cancer , cancer , thyroid , tyrosine kinase inhibitor , oncology , gastroenterology
Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has an anticancer action in patients with differentiated thyroid cancer that is refractory to radioiodine. Knowledge of the efficacy and safety of lenvatinib in patients with anaplastic thyroid cancer (ATC) is limited. Tyrosine kinase inhibitors frequently cause hypothyroidism, but the incidence of hypothyroidism with lenvatinib is unclear.